"Efficacy and Safety of a Novel Gene Therapy (URO-902; PVAX/HSLO) in Fe" by Kenneth Peters, Ekene Enemchukwu et al.
 

Efficacy and Safety of a Novel Gene Therapy (URO-902; PVAX/HSLO) in Female Patients With Overactive Bladder and Urge Urinary Incontinence: Results From a Phase 2A Trial.

Document Type

Conference Proceeding - Restricted Access

Publication Date

5-2022

Publication Title

Journal of Urology

Abstract

Volume

207

Issue

Suppl 5

First Page

e1048

Comments

American Urological Association Annual Meeting, May 13-16, 2022, New Orleans, LA.

International Continence Society Annual Meeting, September 7-10, 2022, Vienna, Austria.

Peters K, Enemchukwu E, Kalota S, Robertson K, Greene H, Badger H, et al. Efficacy and safety of a novel gene therapy (URO-902;PVAX/HSLO) in female patients with overactive bladder and urge urinary incontinence: results from a phase 2A trial. Continence. 2022 Jun;2(Suppl 2):100196. doi:10.1016/j.cont.2022.100196.

DOI

10.1097/JU.0000000000002671.03

Plum Print visual indicator of research metrics
PlumX Metrics
  • Usage
    • Abstract Views: 32
  • Captures
    • Readers: 4
  • Mentions
    • News Mentions: 10
  • Social Media
    • Shares, Likes & Comments: 26
see details

Share

COinS